Sale of stock pursuant to existing 10b5-1 trading plans dated November 22, 2024.

50,962 shares gifted to a trust for the benefit of the reporting person's spouse and for which the reporting person is a trustee on September 12, 2023 and reported on the Form 4 filed on September 13, 2023 were inadvertently left out of the total holdings of the trust in subsequent reports.


Common units representing limited partner interests

Global GP LLC is purchasing common units for the purpose of satisfying obligations pursuant to awards previously granted to directors and officers under the Global Partners LP Long-Term Incentive Plan ("LTIP"). The reporting person disclaims any pecuniary interest in these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for the purpose of Section 16.

The price reported in Column 4 is a weighted average price. These common units were purchased in multiple transactions at prices ranging from $49.15 to $49.71, inclusive. The reporting person undertakes to provide to Global Partners LP, any security holder of Global Partners LP, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common units purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

The price reported in Column 4 is a weighted average price. These common units were purchased in multiple transactions at prices ranging from $50.49 to $51.41, inclusive. The reporting person undertakes to provide to Global Partners LP, any security holder of Global Partners LP, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common units purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.

The price reported in Column 4 is a weighted average price. These common units were purchased in multiple transactions at prices ranging from $50.68 to $51.45, inclusive. The reporting person undertakes to provide to Global Partners LP, any security holder of Global Partners LP, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common units purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Erin Powers Brennan, Attorney-in-Fact for Global GP LLC


Common Shares

On December 20, 2023, the reporting person filed a Form 4 reporting depositions of 2,825 and 2,802 shares to cover tax withholding, which should have been 2,030 and 2,013. The number of shares beneficially owned following this transaction has been adjusted to correct this error.

75% of the options vested on May 16, 2025 and the remaining 25% vested on July 29, 2025.


The Reporting Person received a grant of common stock that is immediately vested pursuant to the Solitron Devices, Inc. 2019 Stock Incentive Plan.


Graves Megan Jane

WELLESLEY HOUSE NORTH, 90 PITTS BAY ROAD

The price reported in Column 4 represents a weighted average price. These Class B common shares were sold in multiple transactions at prices ranging from $23.50 to $24.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.


Represents restricted stock units ("RSUs") granted to the Reporting Person on August 13, 2025 (the "Grant Date") and is subject to the terms and conditions of the Issuer's 2024 Incentive Compensation Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest as follows: one-third upon the first anniversary of the Grant Date, one-third upon the second anniversary of the Grant Date, and one-third upon the third anniversary of the Grant Date.

Includes (a) 13,333 RSUs that are scheduled to vest in two equal installments on June 26, 2026 and June 26, 2027, (b) 214,600 RSUs that are scheduled to vest in three equal installments on March 12, 2026, March 12, 2027 and March 12, 2028, (c) 5,537 shares of deferred stock units ("DSUs") (such shares of common stock underlying such DSUs shall be issued upon the Reporting Person's separation from service with the Issuer), (d) 100,000 RSUs that are scheduled to vest in three equal installments on August 13, 2026, August 13, 2027 and August 13, 2028 and (e) 22,405 shares of common stock beneficially owned by the Reporting Person.

/s/ Brett W. Johnston, as Attorney-In-Fact


The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.15 to $12.45, inclusive.

/s/ Christopher Hilberg, Attorney-in-Fact


Dividend equivalents accrued on Restricted Stock Units ("RSUs") previously awarded pursuant to Issuer's incentive plan. Dividend equivalents accrue when dividends are paid on the common shares underlying the RSUs, and vest proportionally with and are subject to settlement and expiration upon the same terms as the RSUs to which they relate. Dividend equivalents are issued in the form of RSUs, each of which represents a contingent right to receive one share of common stock.

Total includes RSUs.

/s/ Michael Brudoley as attorney-in-fact for Mark Pearson


Common Stock, par value $0.001 per share

Mr. Metz is a partner of the Metz Investments LP account

Mr. Metz is the settlor and trustee of the Adam Metz 2006 Trust, which owns the reported securities. Mr. Metz disclaims beneficial ownership of shares of common stock held by the Adam Metz 2006 Trust, except to the extent of his pecuniary interest therein.


Includes 12,428 restricted stock units which shall be fully vested on the earlier of (i) the one year anniversary of June 10, 2025 or (ii) the day preceding the next annual meeting of stockholders following June 10, 2025, subject to the Reporting Person's continued service through such dates.

/s/ Michael G. Potter, as attorney-in-fact for Sarah M. Kim


The transaction being reported was effected pursuant to a previously established Rule 10b5-1 trading plan dated September 20, 2024.

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.165 to $17.11, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The shares are held by The Siebel Living Trust u/a/d 7/27/93, as amended, of which the Reporting Person is trustee.

The shares are held by First Virtual Holdings, LLC, of which the Reporting Person is Chairman.

The shares are held by Siebel Asset Management, L.P., of which the Reporting Person is the general partner.

The shares are held by Siebel Asset Management III, L.P., of which the Reporting Person is the general partner.

The shares are held by The Siebel 2011 Irrevocable Children's Trust, of which the Reporting Person is co-trustee.


Total includes RSUs.

/s/ Michael Brudoley as attorney-in-fact for Jeffrey Hurd


John Hancock Marathon Asset-Based Lending Fund

Reflects the transfer of Class I Shares by Marathon Asset Management, L.P., the Sub-Advisor of the Issuer (the "Sub-Advisor"), to the Reporting Person as a limited partner of the Sub-Advisor in exchange for no payment.

The Reporting Person is a Managing Partner, the Chief Investment Officer and a limited partner of the Sub-Advisor.


Reflects the transfer of Class I Shares by the Reporting Person to a limited partner of the Reporting Person in exchange for no payment.

Reflects the redemption of Class I Shares by the Issuer.

/s/ Jamie Raboy, Authorized Person of Marathon Asset Management GP, L.L.C.,general partner of Marathon Asset Management, L.P.


Common Stock

Represents restricted stock units ("RSUs") granted on August 12, 2024 that fully vested on August 12, 2025. Each RSU represents a contingent right to receive one share of common stock upon vesting.

RSUs convert into common stock on a one-for-one basis.

Represents RSUs granted on August 13, 2025 and scheduled to fully vest on August 13, 2026. Each RSU represents a contingent right to receive one share of common stock upon vesting. The Reporting Person has reported prior awards of RSUs in Table II of Form 4.

Includes (a) 20,000 RSUs that are scheduled to vest in three equal installments on August 13, 2026, August 13, 2027 and August 13, 2028 and (b) 26,585 shares of common stock beneficially owned by the Reporting Person.

The reported securities include (a) 15,000 deferred stock units ("DSUs") granted under the Issuer's 2012 Incentive Compensation Plan and (b) 6,629 DSUs granted under the Issuer's 2024 Incentive Compensation Plan. The shares of common stock underlying such DSUs shall be issued upon the Reporting Person's separation from service with the Issuer.

/s/ Brett W. Johnston, as Attorney-in-Fact


45,326,620 shares were owned following the reported transaction by the W.K. Kellogg Foundation Trust (the "Trust") of which LaJune Montgomery Tabron, Steve Cahillane, Richard M. Tsoumas and The Northern Trust Company are Trustees and the W.K. Kellogg Foundation (the "Foundation") is the sole beneficiary.

The sales reported on this Form 4 were made pursuant to trading instructions given by the W.K. Kellogg Foundation Trust on May 7, 2024 that are intended to comply with Rule 10b5-1(c) under the Securities and Exchange Act of 1934.

Craig R. Carberry, Deputy General Counsel, The Northern Trust Company, as Corporate Trustee of the W.K. Kellogg Foundation Trust and signing for the W.K. Kellogg Foundation pursuant to a Power of Attorney dated August 30, 2017


The price reported in Column 4 is a weighted average price. These common units were purchased in multiple transactions at prices ranging from $12.34 to $12.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common units purchased at each separate price within the ranges set forth in this footnote.

/s/ Steve Putman, attorney-in-fact for Thomas L. Carter, Jr.


Dividend equivalents accrued on Restricted Stock Units ("RSUs") previously awarded pursuant to Issuer's incentive plan. Dividend equivalents accrue when dividends are paid on the common shares underlying the RSUs, and vest proportionally with and are subject to settlement and expiration upon the same terms as the RSUs to which they relate. Dividend equivalents are issued in the form of RSUs, each of which represents a contingent right to receive one share of common stock.

Total includes RSUs.

/s/ Michael Brudoley as attorney-in-fact for William Eckert


Class A common stock, par value $0.0001 per share

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

The options vested fully on the first anniversary of the grant date.

/s/ Paul Maple, Attorney-in-Fact for Timothy McKenna


Total includes RSUs.

Reporting person's title  is President of Equitable Financial.

/s/ Michael Brudoley as attorney-in-fact for Nick Lane


The Reporting Person received a grant of common stock that is immediately vested pursuant to the Solitron Devices, Inc. 2019 Stock Incentive Plan.


Represents restricted stock units ("RSUs") granted on August 12, 2024 and scheduled to fully vest on August 12, 2025. Each RSU represents a contingent right to receive one share of common stock upon vesting.

Includes (a) 20,000 RSUs that are scheduled to fully vest on August 13, 2026 and (b) 2,500 shares of common stock beneficially owned by the Reporting Person.


Total includes RSUs.

Reporting person's title is Head of Asset Management.

Michael Brudoley as attorney-in-fact for Seth Bernstein


The reporting person transferred these shares as a gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5.

The price reported is a weighted average price. These shares were sold in multiple transaction at prices ranging from $67.06 to $67.28, inclusive.  The reporting person undertakes to provide to Main Street Capital Corporation, any of its security holders, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


/s/ Tiffany Meriweather, Attorney in Fact


Common Stock

Transaction reflects vesting and conversion into shares on a one-for-one basis of restricted stock units previously awarded.

/s/ Kortney Q. Nordrum, Attorney in Fact


The price reported in Column 4 represents a weighted average price. These Class B common shares were sold in multiple transactions at prices ranging from $23.02 to $23.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.


Dividend equivalents accrued on Restricted Stock Units ("RSUs") previously awarded pursuant to Issuer's incentive plan. Dividend equivalents accrue when dividends are paid on the common
shares underlying the RSUs, and vest proportionally with and are subject to settlement and expiration upon the same terms as the RSUs to which they relate. Dividend equivalents are issued in the form of RSUs, each of which represents a contingent right to receive one share of common stock.

Total includes RSUs.

Michael Brudoley as attorney-in-fact for Robin Raju


Class A Common Stock

By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009

The shares were sold in multiple transactions at prices ranging from $71.63 to $72.59, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Shares held following the reported transactions include 127,735 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.

This option was granted for a total of 194,399 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date.

/s/ Daniel Rodriguez as Attorney-in-Fact for Kevin Yeaman


The reported sales transactions were executed at prices ranging from $41.525 to $41.650.  The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were affected.


Common Stock

Common Stock

Common Stock

Reporting person serves as co-trustee with his spouse of a trust established for the benefit of his minor children.

The Restricted Stock Units convert into shares of Common Stock on a one-for-one basis upon vesting.

These RSUs were granted pursuant to the Company's Long-Term Incentive Program (the "LTIP") under its 2024 Omnibus Incentive Plan (the "2024 Plan") and vest equally on the first, second and third anniversary of the Grant Date.

These Performance Based Restricted Stock Units ("PSUs") convert into shares of Common Stock on a one-for-one basis upon vesting.

These PSUs were granted pursuant to the Company's LTIP and are earned in four segments, (1) 16.66% are earned based on performance during 2025, (2) 16.67% are earned based on performance during each of 2026 and 2027 and (3) 50% are
earned based on the Company's three-year performance. The PSUs in each segment can be earned between 50% and 200% based on the Company's performance, provided that the Company's performance exceeds the threshold performance level.
Once earned, the PSUs vest on the third anniversary of the Grant Date.

These PSUs were granted pursuant to the Company's LTIP and are earned between 50% and 200% based on the Company's performance during the 2025-2027 Performance Period, provided that Company performance exceeds the threshold performance level. Once earned, the PSUs vest on the third anniversary of the Grant Date.


The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.

The reporting person transferred these shares as a gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5.


Common Stock

Represents restricted stock units ("RSUs") granted on August 12, 2024 that fully vested on August 12, 2025. Each RSU represents a contingent right to receive one share of common stock upon vesting.

RSUs convert into common stock on a one-for-one basis.

These shares represent shares of common stock of the Issuer held by the Reporting Person, of which 5,000 are held jointly by the Reporting Person and his spouse.

Represents RSUs granted on August 13, 2025 and scheduled to fully vest on August 13, 2026. Each RSU represents a contingent right to receive one share of common stock upon vesting. The Reporting Person has reported prior awards of RSUs in Table II of Form 4.

Includes (a) 20,000 RSUs that are scheduled to fully vest on August 13, 2026 and (b) 92,585 shares of common stock beneficially owned by the Reporting Person, of which 5,000 are held jointly by the Reporting Person and his spouse.

The reported securities include (a) 63,657 deferred stock units ("DSUs") granted under the Issuer's 2012 Incentive Compensation Plan and (b) 11,952 DSUs granted under the Issuer's 2024 Incentive Compensation Plan. The shares of common stock underlying such DSUs shall be issued upon the Reporting Person's separation from service with the Issuer.


Reflects the transfer of Class I Shares by Marathon Asset Management, L.P., the Sub-Advisor of the Issuer (the "Sub-Advisor"), to the Reporting Person as a limited partner of the Sub-Advisor in exchange for no payment.

Includes 840.57 Class I Shares received by the Reporting Person pursuant to the Issuer's dividend reinvestment plan. Such acquisitions are exempt from Section 16 concurrent reporting requirements pursuant to Rule 16a-11.

On December 13, 2024, the Reporting Person filed a Form 4 (the "Original Form 4") that did not disclose certain Class I Shares received by the Reporting Person pursuant to the Issuer's dividend reinvestment plan. This Form 4/A is being filed to amend and restate Table I of the Original Form 4, including the footnotes thereto, to disclose the number of Class I Shares received by the Reporting Person pursuant to the Issuer's dividend reinvestment plan.

The Reporting Person is a Portfolio Manager and a limited partner of the Sub-Advisor.


Reflects transfers of Class I Shares by the Reporting Person to limited partners of the Reporting Person in exchange for no payments.

Includes 34,969.620 Class I Shares received by the Reporting Person pursuant to the Issuer's dividend reinvestment plan. Such acquisitions are exempt from Section 16 concurrent reporting requirements pursuant to Rule 16a-11.

On December 13, 2024, the Reporting Person filed a Form 4 (the "Original Form 4") that disclosed an erroneous number of Class I Shares received by the Reporting Person pursuant to the Issuer's dividend reinvestment plan. This Form 4/A is being filed to amend and restate Table I of the Original Form 4, including the footnotes thereto, to disclose the correct number of Class I Shares received by the Reporting Person pursuant to the Issuer's dividend reinvestment plan.


Common Stock


Shares withheld to satisfy the withholding tax obligations resulting from the vesting on August 12, 2025 of certain restricted stock units granted to the reporting person in 2020 under the Kaiser Aluminum Corporation 2016 Equity and Incentive Compensation Plan.

Includes 14,431 shares acquired pursuant to grants of restricted stock units.

/s/ John M. Donnan, with power of attorney for Jason Walsh


Includes 11,044 shares acquired pursuant to grants of restricted stock units.

/s/ John M. Donnan, with power of attorney for Blain Tiffany


Common Stock

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.34 to $198.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Balance in AbbVie Savings program as of August 1, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.

The reporting person disclaims beneficial ownership of all securities held by her spouse.

Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,124 on February 18, 2017, 14,123 on February 18, 2018, and 14,123 on February 18, 2019.

/s/  T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt


Dividend equivalents accrued on Restricted Stock Units ("RSUs") previously awarded pursuant to Issuer's incentive plan. Dividend equivalents accrue when dividends are paid on the common
shares underlying the RSUs, and vest proportionally with and are subject to settlement and expiration upon the same terms as the RSUs to which they relate. Dividend equivalents are issued in the form
of RSUs, each of which represents a contingent right to receive one share of common stock.

Total includes RSUs.

Michael Brudoley as attorney-in-fact for Jose Gonzalez


This price represents the weighted average sales price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $25.475 to $25.4765. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.

/s/ Elizabeth H. Townsend - Attorney-in-Fact


Includes 872.42 shares acquired under the Amerant Bancorp Inc. Employee Stock Purchase Plan on May 30, 2025.

/s/ Julio V. Pena, as Attorney-in-Fact for Juan Esterripa


Kiniksa Pharmaceuticals International, plc

Class A Ordinary Shares

Class A Ordinary Shares

Class A Ordinary Shares

Class A Ordinary Shares

Class A Ordinary Shares

Class A Ordinary Shares

Class A Ordinary Shares

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.06 and $32.685. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.1301 and $33.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.82 and $33.41. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.

The option is fully vested and exercisable.


Common Stock

The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.


The Reporting Person received a grant of common stock that is immediately vested pursuant to the Solitron Devices, Inc. 2019 Stock Incentive Plan.


Shares withheld for the payment of a tax liability related to the vesting and distribution of restricted stock units.


Represents restricted stock units ("RSUs") granted to the Reporting Person on August 13, 2025 (the "Grant Date") and is subject to the terms and conditions of the Issuer's 2024 Incentive Compensation Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest as follows: one-third upon the first anniversary of the Grant Date, one-third upon the second anniversary of the Grant Date, and one-third upon the third anniversary of the Grant Date. The Reporting Person has reported prior awards of RSUs in Table II of Form 4.

Includes (a) 13,333 RSUs, which the reporting person previously reported on Table II of Form 4, that are scheduled to vest in two equal installments on June 26, 2026 and June 26, 2027, (b) 40,000 RSUs that are scheduled to vest in three equal installments on August 13, 2026, August 13, 2027 and August 13, 2028 and (c) 34,250 shares of common stock beneficially owned by the Reporting Person.


The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.


Common Stock

Represents restricted stock units ("RSUs") granted on August 12, 2024 that fully vested on August 12, 2025. Each RSU represents a contingent right to receive one share of common stock upon vesting.

RSUs convert into common stock on a one-for-one basis.

Represents RSUs granted on August 13, 2025 and scheduled to fully vest on August 13, 2026. Each RSU represents a contingent right to receive one share of common stock upon vesting. The Reporting Person has reported prior awards of RSUs in Table II of Form 4.

Includes (a) 20,000 RSUs that are scheduled to fully vest on August 13, 2026 and (b) 28,485 shares of common stock beneficially owned by the Reporting Person.

These reported securities represent deferred stock units ("DSUs") granted under the Issuer's 2024 Incentive Compensation Plan. The shares of common stock underlying such DSUs shall be issued upon the Reporting Person's separation from service with the Issuer.

/s/ Brett W. Johnston, as Attorney-in-Fact


/s/ Jennifer L. Deacon, Power of Attorney


Common Stock

Represents restricted stock units granted by the Issuer pursuant to dividend equivalent rights on previously awarded restricted stock units.  The restricted stock units are fully vested, have no expiration, and will be settled in shares of the Issuer's common stock, on a one-for-one basis, upon the reporting person's separation from service with the Issuer.

/s/ Jenny B. Neslin, Attorney-in-Fact for M. Christian Mitchell


Includes (a) 16,667 RSUs, which the reporting person previously reported on Table II of Form 4, that are scheduled to vest in two equal installments on June 26, 2026 and June 26, 2027, (b) 50,000 RSUs that are scheduled to vest in three equal installments on August 13, 2026, August 13, 2027 and August 13, 2028 and (c) 14,233 shares of common stock beneficially owned by the Reporting Person.

These securities represent deferred stock units granted under the Issuer's 2012 Incentive Compensation Plan held by the Reporting Person.


Class A common stock, par value $0.01 per share

Class B common stock, par value $0.01 per share

Class A Common Stock

The price reported in Column 4 is a weighted average price. The prices sold ranged from $25.05 to $25.96. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Includes 6,141 shares held in a 401(k) account.

The price reported in Column 4 is a weighted average price. The prices sold ranged from $26.39 to $27.30. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is a weighted average price. The prices sold ranged from $27.40 to $28.39. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is a weighted average price. The prices sold ranged from $28.39 to $28.96. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Each share of Class B Common Stock is convertible at the option of the reporting person into one share of Class A Common Stock ("Common Stock") of Dream Finders Homes, Inc. and has no expiration date.

Trust established for the benefit of the reporting person's children.

Shares held by POZ Holdings, Inc., which is controlled by the reporting person.

Mr. Zalupski entered into prepaid variable forward sale contracts on August 14, 2024, December 5, 2024, and June 5, 2025, respectively, whereby Mr. Zalupski pledged an aggregate of 3,000,000 shares (the "Pledged Shares") of Class B Common Stock to secure obligations under the contracts, and retained dividend and voting rights in the Pledged Shares during the term of the pledge.

(Continued from footnote 9) The contracts obligate Mr. Zalupski to deliver to the buyer, on the applicable settlement date for each of the 10 components, up to one hundred percent (100%) of the number of Pledged Shares for such component or, at Mr. Zalupski's option, an equivalent amount of cash. The number of shares to be delivered to the buyer on the settlement date (or on which to base the amount of cash to be delivered to the buyer on the settlement date) is to be determined as follows: (a) if the volume-weighted average price of the Class A Common Stock on the designated valuation date for the applicable component within the period from 8/16/2027 to 8/27/2027 with respect to 1,000,000 shares, 5/15/2028 to 5/26/2028 with respect to 1,000,000 shares, and 3/20/2029 to 4/3/2029 with respect to 1,000,000 shares (each, a "Settlement Price") is less than or equal to $22.12, $24.01 or $17.27, as applicable, (the "Floor Price"),

(Continued from Footnote 10) Mr. Zalupski will deliver to the buyer all of the Pledged Shares for the applicable component; (b) if such Settlement Price is greater than the Floor Price but less than or equal to $55.30, $66.02 or $37.78, as applicable (the "Cap Price"), Mr. Zalupski will deliver to the buyer the number of shares equal to one hundred percent (100%) of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is such Settlement Price and (c) if such Settlement Price is greater than the Cap Price, Mr. Zalupski will deliver to the buyer the number of shares equal to one hundred percent (100%) of Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price plus the excess of such Settlement Price over the Cap Price, and the denominator of which is such Settlement Price.


Represents the weighted average sale price for the entire number of shares sold.  The actual sale prices range between $116.00 and $116.39.  Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.


The transactions were executed pursuant to a Rule 10b5-1 plan.

This transaction was executed in multiple trades at prices ranging from $45.00 to $45.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.

/s/ Jeffrey J. LaValle, under Power of Attorney  for Timothy J. Jahnke


By: Jennifer Neil For: Manuel Perez de la Mesa


By: Hampstead Park Environmental Services Investment Fund LLC

Common Stock

Represents restricted stock units ("RSUs") granted on August 12, 2024 that fully vested on August 12, 2025. Each RSU represents a contingent right to receive one share of common stock upon vesting.

RSUs convert into common stock on a one-for-one basis.

These shares represent shares of common stock of the Issuer held by Mr. Friedberg.

Represents RSUs granted on August 13, 2025 and scheduled to fully vest on August 13, 2026. Each RSU represents a contingent right to receive one share of common stock upon vesting. The Reporting Person has reported prior awards of RSUs in Table II of Form 4.

Includes (a) 20,000 RSUs that are scheduled to fully vest on August 13, 2026 and (b) 20,585 shares of common stock beneficially owned by the Reporting Person.

The reported securities include (a) 18,153 deferred stock units ("DSUs") granted under the Issuer's 2012 Incentive Compensation Plan and (b) 21,431 DSUs granted under the Issuer's 2024 Incentive Compensation Plan. The shares of common stock underlying such DSUs shall be issued upon Mr. Friedberg's separation from service with the Issuer.

This Form 4 is filed jointly by Hampstead Park Environmental Services Investment Fund LLC ("Hampstead Park Environmental"), Daniel Friedberg and Hampstead Park Capital Management, LLC ("Hampstead Park Capital"). Hampstead Park Capital is the sole member of Hampstead Park Environmental, and Mr. Friedberg is the Chief Executive Officer of Hampstead Park Capital; each may therefore be deemed to control Hampstead Park Environmental. In addition, Mr. Friedberg is a Director of the Issuer.


The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $13.80 to $14.11, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $13.81 to $14.40, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.


Represents the weighted average sale price for the entire number of shares sold.  The actual sale prices range between $115.575 and $116.50.  Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.


Gift, not applicable.

Represents (i) 112,672 shares held by the Bergman Family 2010 Trust #2, of which Mrs. Bergman, Stanley M. Bergman's wife, is a co-trustee and a beneficiary; (ii) 21 shares held by Mrs.Bergman; (iii) 329,410 shares held by the Bergman Family 2010 Trust #2, LLC, of which Mrs. Bergman is a manager; and (iv) 23,858 shares held by the SBMB GST Trusts Partners LLC, of which Mrs. Bergman is a manager.

Reflects the reporting person's interest in equivalent shares of Henry Schein common stock held by the unitized stock fund in the Henry Schein, Inc. 401(k) Savings Plan (the "Plan").  The unitized stock fund consists of Henry Schein common stock and cash or cash equivalents. The number of shares attributed to the reporting person as a participant in the Plan and expressed as equivalent shares has been calculated based on the closing price of Henry Schein common stock on August 13, 2025.

/s/ Jennifer Ferrero (as attorney-in-fact for Stanley M. Bergman)


Common Stock

Represents RSUs granted on August 13, 2025 that are scheduled to fully vest on August 13, 2026. Each RSU represents a contingent right to receive one share of common stock upon vesting. The Reporting Person has reported prior awards of RSUs in Table II of Form 4.

Includes (a) 20,000 RSUs that are scheduled to fully vest on August 13, 2026 (b) 24,335 shares of common stock beneficially owned by the Reporting Person.

The reported securities include (a) 18,027 deferred stock units ("DSUs") granted under the Issuer's 2012 Incentive Compensation Plan and (b) 11,910 DSUs granted under the Issuer's 2024 Incentive Compensation Plan. The shares of common stock underlying such DSUs shall be issued upon the Reporting Person's separation from service with the Issuer.


Securities withheld to pay withholding taxes on vested restricted stock units ("RSUs") exempt under Rule 16b-3.

Includes unvested restricted stock units ("RSUs") and amounts accrued for dividend equivalent units on such RSUs.

/s/ Daniel S. Kelly, Attorney-in-Fact for James W. Alvey


Family trust


Reflects shares withheld to cover the reporting person's tax withholding obligations in connection with the vesting of restricted stock units.

Title: Chief Marketing and Strategy Officer

Jennifer Giampietro, as Attorney-in-Fact


This transaction was executed in multiple trades.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Includes 124,840 unvested shares of restricted stock


The reporting person transferred these shares as a gift pursuant to a transaction exempt from Section 16(b) under Rule 16b-5.


Common Stock

Restricted stock units that vest four years from the date of grant and are settled in shares of Applied common stock.

Stock-only stock appreciation rights which become exercisable in annual increments of 25% commencing one year after the date of grant.

/s/ Patricia A. Comai, POA for Richard M. Wagner


Shares sold were directly owned by Azzurro Capital Inc.

Sale prices for the shares sold ranged from $10.11 to $10.58 per share.

The reporting person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each price.

The "Amount of Securities Beneficially Owned Following Reported Transaction(s)" represents shares held by Azzurro Capital Inc.

Indirect ownership applies to Ralph Bartel and the Ralph Bartel 2005 Trust.

Sale prices for the shares sold ranged from $10.43 to $10.58 per share.


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.17 to $116.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

/s/ Megan L. Mercer, attorney-in-fact for Mr. Beaird


The reporting person is a member of a limited liability company that is a member of the limited liability company that owns the reported securities, and the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

The reporting person is a shareholder of the corporation that owns the reported securities, and the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

The reporting person is a trustee of a trust that is a member of the limited liability company that owns the reported securities, and the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Robert D. Vilsack, Attorney-In-Fact for Matthew V. Crawford


The Reporting Person received a grant of common stock that is immediately vested pursuant to the Solitron Devices, Inc. 2019 Stock Incentive Plan.


Common Shares

Common Shares

Common Shares

Reporting person sold Common Shares at an average price of $38.0482 of which the Common Shares were sold in multiple transactions at prices ranging from $38.00 and $38.10. The reporting person undertakes to provide to the SEC, the Issuer and any security holder, the full information regarding the number of shares and the prices at which the shares were sold.

Reporting person is one of four trustees of a voting trust which is record owner of these  Common Shares and which files its holdings on a form 4. The shares reported are held by respective reporting person and her family members that have a pecuniary interest in such securities. Includes
693,677 Common Shares held by a family partnership of which reporting person is a general partner.

Series A Common shares are convertible on a share for share basis into common.

Gift to children

Reporting person is one of four trustees of a voting trust which is record owner of these  Series A Common Shares and which files its holdings on a form 4. The shares reported are held by respective reporting person and her family members that have a pecuniary interest in such securities. Includes
756,243 Series A Common Shares held by a family partnership of which reporting person is a general partner.


Common Stock

Each restricted stock unit is the economic equivalent of one share of Liquidity Services, Inc. Common Stock.

These restricted stock units vest one year from the grant date.

/s/ Mark A. Shaffer, by power of attorney


Held in a custodial IRA for the benefit of Reporting Person's son, for which the Reporting Person serves as custodian.

Held in a custodial IRA for the benefit of Reporting Person's daughter, for which the Reporting Person serves as custodian.

The Reporting Person no longer has a reportable beneficial interest in 151,725 shares held by her now ex-spouse.  Such shares were included in the Reporting Person's prior ownership report.

/s/Peter J. Rivas as attorney-in-fact for Anna U. Loengard


Common Stock

Restricted stock units that vest three years from the date of grant and are settled in shares of Applied common stock.

Performance shares "banked" as a result of 2025 performance. Performance shares vest at end of three-year program and are settled in shares of Applied common stock.

Shares withheld by Registrant to satisfy tax withholding obligations on vesting of performance shares.

Stock-only stock appreciation rights which become exercisable in annual increments of 25% commencing one year after the date of grant.

/s/ Patricia A. Comai POA for David K. Wells


Represents a grant of time-vesting restricted stock, which will vest on January 14, 2028.

/s/Robert L. Holladay, Jr., on behalf of Melanie Boulden, pursuant to a power of attorney


Represents 240,341 shares owned by Cedar Creek Partners LLC, an investment partnership, for which Eriksen Capital Management LLC ("ECM") is Managing Member, and 24,055 shares owned by managed accounts of ECM. The respective owners of the managed accounts are responsible to vote the shares. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

This Form 4 is filed jointly by ECM, Cedar Creek Partners LLC, and Mr. Eriksen. By virtue of ECM's Investment Advisory Agreement with the clients of ECM, Mr. Eriksen may be deemed to beneficially own the shares owned by Cedar Creek Partners and the managed accounts.

Represents shares owned by Eriksen Family LLC, of which Mr. Eriksen is the Managing Member. The LLC is owned by Mr. Eriksen and his four adult children. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Mr. Eriksen may be deemed to beneficially own the shares owned by Eriksen Family LLC.


Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person.


Common stock, par value $0.001

The price reported in this row of Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.000 to $113.340, inclusive. The reporting person undertakes to provide to ESAB Corporation, any security holder of ESAB Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for the purposes of Section 16 or for any other purpose.


Debt settlement with respect to an outstanding loan.


The price in Column 4 is a weighted average price. The actual prices received ranged from $40.0101 to $40.0110. The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

Miyuki P. Oshima as attorney-in-fact for Isabelle McKenzie


This transaction was conducted in British Pounds. The per share purchase price of GBP3.27 was converted into U.S. Dollars at the conversion rate of GBP1 = USD1.35.


Held by the Catherine Spear Revocable Trust

Class A Common Stock

Class A Common Stock

REPRESENTS THE AGGREGATE NUMBER OF SHARES SOLD BY THE REPORTING PERSON SOLELY TO COVER REQUIRED TAXES AND FEES DUE UPON THE VESTING AND SETTLEMENT OF RESTRICTED STOCK UNITS ("RSUs"). THE SALES WERE MADE PURSUANT TO A 10B5-1 INSTRUCTION LETTER DELIVERED TO THE ISSUER ON MAY 13, 2025, AND NONE OF THE SHARES REPORTED AS SOLD ON THIS FORM 4 WERE SOLD FOR ANY REASON OTHER THAN TO COVER REQUIRED TAXES AND FEES.

1,460,886 of these securities are RSUs, each representing a contingent right to receive one share of the Issuer's Class A Common Stock. In addition to the securities reported in this column, the
Reporting Person holds 5,469,161 shares of the Issuer's Class B Common Stock directly and indirectly through various trusts, which are convertible at any time at the option of the Reporting Person into
an equal number of shares of Class A Common Stock, and 18,958,606 shares of the Issuer's Class A Common Stock underlying vested options, neither of which are reported on this Form 4.

The Reporting Person is a managing member of Hollywood Capital Partners LLC and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

All shares underlying this option have vested.

The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 12, 2025 (the "Repricing Date"). The Option Repricing applies to 727,097 fully vested options originally granted to the Reporting Person on May 26, 2021 with an original exercise price of $22.00. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $6.63 per share, the closing price of the Issuer's Class A Common Stock on the Repricing Date. The vesting schedule  of the repriced options has also been extended as reported herein. There is no change to the expiration date of, or number of shares underlying, the repriced options. For more information, see Part II, Item 5. "Other Information" in the Issuer's Form 10-Q filed with the SEC on August 7, 2025.

The option vests and becomes exercisable in 24 equal monthly installments, with the first installment vesting on September 12, 2025.

/s/ Danielle Warner as Attorney-in-Fact for Catherine Spear


The price in Column 4 is a weighted average price. The actual prices received ranged from $40.0400 to $40.0500. The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

Miyuki P. Oshima as attorney-in-fact for Stefan Demmerle


Common Stock

Restricted stock units that vest three years from the date of grant and are settled in shares of Applied common stock.

Performance shares "banked" as a result of 2025 performance. Performance shares vest at end of three-year program and are settled in shares of Applied common stock.

Shares withheld by Registrant to satisfy tax withholding obligations on vesting of performance shares.

Stock-only stock appreciation rights which become exercisable in annual increments of 25% commencing one year after the date of grant.

/s/ Patricia A. Comai POA for Kurt Loring


The price reported in this column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.44, inclusive. The Reporting Person undertakes to provide to Resideo Technologies, Inc. ("Resideo"), any security holder of Resideo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

/s/ Jeannine J. Lane, as Attorney-in-Fact for Jay L. Geldmacher


Forward sale contract (potential obligation to sell)

Common Stock

Common Stock

Common Stock

Common Stock

These securities are held directly by PJAM IBP Holdings, Inc. ("PJAM"). The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein. IBP Holding Company is the sole shareholder of PJAM.

These securities are held directly by Installed Building Systems, Inc. ("IBS"). Mr. Edwards disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The Reporting Persons remain the beneficial owners of all Pledged Shares, as defined in Footnote 4, reported in Table II to the extent of his or its pecuniary interest therein. Mr. Edwards is the sole beneficial owner of the shares reported in Table I as directly owned.

The securities are held by a trust for the benefit of one of Mr. Edwards' children. Mr. Edwards disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

As previously reported, Installed Building Systems, Inc. ("IBS"), entered into two prepaid variable forward sale contracts on each of September 2023, November 2023 and May 2024 with an unaffiliated third party buyer.  In each of the September and November transactions, IBS pledged 450,000 shares, or 225,000 shares per contract and 900,000 shares in the aggregate, and in the May transaction, IBS pledged 250,000 shares, or 125,000 shares per contract (collectively, the "Pledged Shares") of Installed Building Products, Inc. common stock ("Common Stock").  The Pledged Shares secure its obligations under the contracts, and IBS retained dividend and voting rights in the Pledged Shares during the term of the pledge. The contracts obligate IBS to deliver to the buyer, on the applicable settlement date for each component referred to in footnote 9 below, up to one hundred percent (100%) of the number of Pledged Shares for such component or, at IBS' option, an equivalent amount of cash.

On August 12, 2025, IBS and the buyer entered into an amendment to the September 2023 forward sale contract (the "September Amendment Agreement") and the May 2024 forward sale contract (the "May Amendment Agreement" and collectively, the "Amendment Agreements").  The September Amendment Agreement amends certain terms of one of the forward sale contracts entered into in September 2023, covering 225,000 shares of Common Stock, including (i) extending the settlement dates for the components from August 14, 2025 to August 22, 2025 to the new settlement dates from May 24, 2027 to June 4, 2027, (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 7 to 9, with appropriate adjustments for the number of shares to be delivered on the respective settlement date for each component.

(Continued from Footnote 5) The May Amendment Agreement amends certain terms of one of the forward sale contracts entered into in May 2024, covering 125,000 shares of Common Stock, including (i) extending the settlement dates for the components from August 14, 2025 to August 22, 2025 to the new settlement dates from November 16, 2026 to November 23, 2026, (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) reducing the number of components from 7 to 6, with appropriate adjustments for the number of shares to be delivered on the respective settlement date for each component.

The number of shares of Common Stock to be delivered to the buyer on the settlement date (or on which to base the amount of cash to be delivered to the buyer on such settlement date) under each Amendment Agreement is to be determined as follows: (a) if the VWAP of the Common Stock on the designated valuation date for the applicable component (each, a "Settlement Price") is less than or equal to $257.6320 (the "Floor Price"), IBS will deliver to the buyer all of the Pledged Shares for the applicable component;

(Continued from Footnote 7) (b) if such Settlement Price is greater than the Floor Price but less than or equal to $319.4637 (the "Cap Price"), IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is such Settlement Price; and (c) if such Settlement Price is greater than the Cap Price, IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price plus the excess of such Settlement Price over the Cap Price, and the denominator of which is such Settlement Price.

Each component is exercisable on the same date as it expires, and the expiration dates for the components occur from May 24, 2027 to June 4, 2027 under the September Amendment Agreement and November 16, 2026 to November 23, 2026 under the May Amendment Agreement.

These securities are held directly by IBS. Mr. Edwards disclaims beneficial ownership in the reported securities except to the extent of his pecuniary interest therein.

The Reporting Persons currently retain ownership of all shares of Installed Building Products, Inc. common stock that are subject to the Pledge Agreement and rights related thereto, including all voting rights.

/s/ Michael T. Miller, Attorney-in-Fact for Installed Building Systems, Inc.


Common Stock

Consists of shares withheld by the issuer to satisfy the reporting person's exercise price and tax withholding obligation upon the exercise of stock options.

Fully vested.

/s/ Jeannine J. Lane, as Attorney-in-Fact for Stephen M. Kelly


Includes unvested RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plans.

/s/ Paul Sharobeem, attorney-in-fact for Matt Aboud


Common Stock

Following a reconciliation of the reporting person's ownership records, the balance includes 352 shares that were inadvertently omitted from the reporting person's prior Form 4s.

The price reported in this column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.31 to $31.345, inclusive. The Reporting Person undertakes to provide to Resideo Technologies, Inc. ("Resideo"), any security holder of Resideo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Fully vested.


Non-qualified Stock Option (Right to Buy)

Common Stock

As indicated by the checkbox above, this transaction was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 9, 2025.

Shares held in the reporting person's name or in the Marc R. Benioff Revocable Trust.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $229.8500 to $230.4600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $230.9800 to $231.7086 inclusive.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $232.2800 to $233.2738 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $233.6179 to $234.6054 inclusive.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $234.7900 to $235.7779 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $235.8100 to $236.7400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $236.8300 to $237.2800 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Shares held in the Marc Benioff Fund LLC (the "Fund").  Fund interests are held in the reporting person's name or in trust.

Option vests over four years at the rate of 25% on March 22, 2020, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.

/s/ Andrew Leeds, Attorney-in-Fact for Marc Benioff


The reported sale of 13,334 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2025.

/s/ Alexandria M. Crist by Power of Attorney


Common Stock

Restricted stock units that vest three years from the date of grant and are settled in shares of Applied common stock.

Performance shares "banked" as a result of 2025 performance. Performance shares vest at end of three-year program and are settled in shares of Applied common stock.

Stock-only stock appreciation rights which become exercisable in annual increments of 25% commencing one year after the date of grant.

/s/ Patricia A. Comai, POA for Jon S. Ploetz


Common Stock

Options vests 1/3 per year beginning on the first anniversary of the grant date.


These shares were issued to the reporting person as part of her compensation for service as a director of the registrant.

/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: DEBORA B. TOMLIN


Common Stock, par value $0.0001 per share

Common Stock

Shares surrendered to pay tax liability due on vesting of Restricted Stock Units

Each restricted stock unit represents a contingent right to receive one share of PHLT's common stock. The units were awarded at no cost to the Reporting Person.

Restricted Stock Unit Award was granted on August 5, 2024 (the "Grant Date"). These Restricted Stock Units shall be allocated into the following three tranches: (i) Tranche 1, consisting of 52,105 Restricted Stock Units, (ii) Tranche 2, consisting of 52,105 Restricted Stock Units and (iii) Tranche 3, consisting of 53,684 Restricted Stock Units. Each Tranche shall vest upon the achievement of the applicable Target Revenue Amount during a Performance Period, and subject to Reporting Person's continuous service through each vesting date. "Target Revenue Amount" shall mean the Company's trailing twelve month Healthcare revenue for a Performance Period as reported in the Company's financial statements filed with the Securities and Exchange Committee on Form 10-K or Form 10-Q, as applicable. Each Target Revenue Amount is measured on the trailing twelve month Healthcare revenue of the Company for the preceding twelve months, measured on a quarterly basis (each, a "Performance Period").

For Tranche 1, Reporting Person shall have up to three years from the Grant Date for the Company to achieve the Tranche 1 Target Revenue Amount of $135M. If the Tranche 1 Target Revenue Amount is achieved before 12 months, Reporting Person vests in the Tranche 1 RSUs at 12 months. If the Tranche 1 Target Revenue Amount is achieved in month 13 - 36, Reporting Person vests in the Tranche 1 RSUs whenever the Tranche 1 Target Revenue Amount is achieved. If the Tranche 1 Target Revenue Amount is not achieved by 36 months, the RSUs tied to Tranche 1 are forfeited.

For Tranche 2, Reporting Person shall have up to three years to achieve the Tranche 2 Target Revenue Amount of $155M. If the Tranche 2 Target Revenue Amount is achieved before 24 months, Reporting Person vests in the Tranche 2 RSUS at 24 months. If the Tranche 2 Target Revenue Amount is achieved in month 25 - 36, Reporting Person vests in the Tranche 2 RSUs whenever the Tranche 2 Target Revenue Amount is achieved. If the Tranche 2 Target Revenue Amount is not achieved by 36 months, the RSUs tied to Tranche 2 are forfeited.

For Tranche 3, Reporting Person shall have up to four years to achieve the Tranche 3 Target Revenue Amount of $175M. If the Tranche 3 Target Revenue Amount is achieved before 36 months, Reporting Person vests in the Tranche 3 RSUs at 36 months. If the Tranche 3 Target Revenue Amount is achieved in month 37 - 48, Reporting Person vests in the Tranche 3 RSUs whenever the Tranche 3 Target Revenue Amount is achieved. If the Tranche 3 Target Revenue Amount is not achieved by 48 months, the RSUs tied to Tranche 3 are forfeited.

/s/ Rohit Ramchandani, Attorney-in-Fact for Simeon M. Kohl


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $161.27 to $162.19, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $162.27 to $163.00, inclusive.


Common Stock

Options vests 1/3 per year beginning on first anniversary of grant date.


Represents a grant of restricted stock units, which vest over a three-year period from the grant date, with equal installments vesting on each of the first, second and third anniversaries of the grant date.

On July 10, 2024, the issuer effected a 1-for-20 reverse split of the issuer's common stock, resulting in proportionate adjustments to the number of shares of Class A common stock beneficially owned by the reporting person, including shares underlying outstanding restricted stock units ("RSUs"). Accordingly, the securities reported on this Form 4 have been adjusted to reflect the 1-for-20 reverse stock split.

/s/ Anna Nesterova as attorney-in-fact for Roy Schoenberg


/s/ Anna Nesterova as attorney-in-fact for Ido Schoenberg


Common Stock

Performance shares "banked" as a result of 2025 performance.  Performance shares vest at end of three-year program and are settled in shares of Applied common stock.

Shares withheld by Registrant to satisfy tax withholding obligations on vesting of performance shares.

/s/ Patricia A . Comai, POA for Jason W. Vasquez


Class A Common Stock

Sold pursuant to the 10b5-1 Plan adopted by SFS Corp on March 17, 2025.

Represents the weighted average price of shares sold. The price of the shares sold ranged from $4.65 to $5.06 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each price.

These securities are held directly by SFS Corp, a 10% holder of the Issuer, and indirectly by Mat Ishbia.  Mat Ishbia is the Chief Executive Officer and sole director of SFS Corp and serves as the investment advisor to the trust that owns the voting securities of SFS Corp, and therefore exercises all voting and dispositive power of the securities held by SFS Corp.  In addition, trusts for the benefit of Mat Ishbia and his immediate family are shareholders of SFS Corp.  By virtue of its relationship with Mat Ishbia, a director and the CEO of the Issuer, SFS Corp may be deemed to be a director by deputization.

Represents the weighted average price of shares sold. The price of the shares sold ranged from $5.08 to $5.63 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each price.

Represents the weighted average price of shares sold. The price of the shares sold ranged from $5.32 to $5.56 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each price.

These shares are held directly by Mat Ishbia and SFS Corp. has no interests in these shares.

These Restricted Stock Units ("RSUs") convert to Class A Common Stock on a one-for-one basis.

These RSUs vest on March 1, 2026. The RSUs were granted pursuant to the 2020 Omnibus Incentive Plan.


Common Stock


Common

Common

Common

/s/ Nicole Y. Lamb-Hale, Attorney-in-Fact


Common Stock

Options vests 20% per year beginning on first anniversary of grant date.


The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $190.5000 to $191.4950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $191.5000 to $192.4900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $192.5000 to $192.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares are directly owned by the GlobalStar DAF, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.


The purchases reported herein were effected pursuant to a Rule 10b5-1 plan adopted by Hill City Holdings, LP ("Hill City") on June 5, 2025.

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $12.27 to $12.755. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The securities are held of record by Hill City. ECP ControlCo, LLC is the managing member of Energy Capital Partners IV, LLC, which is the general partner of Energy Capital Partners GP IV, LP, which is the general partner of each of (i) Energy Capital Partners IV-A, LP, (ii) Energy Capital Partners IV-B, LP, (iii) Energy Capital Partners IV-C, LP, and (iv) Energy Capital Partners IV-D, LP (the "Funds"). Energy Capital Partners GP IV, LP is also the general partner of Energy Capital Partners IV-B (Hill City IP), LP ("Hill City IP"). Each of (i) Energy Capital Partners IV-A, LP, (ii) Hill City IP, (iii) Energy Capital Partners IV-C, LP, and (iv) Energy Capital Partners IV-D, LP are the members of Hill City Holdings GP, LLC, which is the general partner of Hill City.

ECP ControlCo, LLC is controlled by its board of managers, which consists of Douglas Kimmelman, Peter Labbat, Tyler Reeder, Rahman D'Argenio, Raoul Hughes and Xavier Robert, all of whom collectively share the power to vote and dispose of the securities beneficially owned by ECP ControlCo, LLC. As a result of these relationships, each of the foregoing entities and individuals may be deemed to share beneficial ownership of the securities held of record by Hill City. Each such entity and individual disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein.

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $12.8041 to $13.12. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Due to filing limitations of the electronic filing system, each of ECP ControlCo, LLC, Energy Capital Partners IV, LLC, Energy Capital Partners GP IV, LP, Energy Capital Partners IV-A, LP, Energy Capital Partners IV-B, LP, Energy Capital Partners IV-C, LP, Energy Capital Partners IV-D, LP and Energy Capital Partners IV-B (Hill City IP), LP are filing a separate Form 4.


Non-Qualified Stock Option (right to buy)

Common Stock

These shares represent the payment of the option exercise price and tax liability by withholding securities.

By: Robyn B. Martin For: POA for John Anderson


An award of Restricted Units granted under the USA Compression Partners, LP Long-Term Incentive Plan that will vest 60% on December 5, 2027 and 40% on December 5, 2029, generally contingent upon the reporting person's continued employment with USA Compression Partners, LP (the "Issuer") or one of its affiliates on each applicable vesting date.

The Reporting Person is the Vice President and Chief Operating Officer of USA Compression GP, LLC, the general partner of the Issuer (the "General Partner"). The Issuer is managed by the directors and executive officers of the General Partner.


The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025.

/s/Heidi A. Sepanik, Corporate Secretary, Visteon Corporation on behalf of Robert R. Vallance


The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.32 to $145.315 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3).

Reported amount includes 243,455 vested and unvested restricted stock units ("RSUs") granted under the Apollo Global Management, Inc. 2019 Omnibus Equity Incentive Plan. Each RSU represents the contingent right to receive, in accordance with the issuance schedule set forth in the applicable RSU award agreement, one share of common stock of the Issuer for each vested RSU. The RSUs vest in installments in accordance with the terms of the applicable RSU award agreement, provided the reporting person remains in service through the applicable vesting date.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.32 to $145.665 inclusive.

Held by the 2025 Martin Kelly Gift Trust, a trust over which the reporting person exercises sole voting and investment control, and for which members of the reporting person's immediate family are the beneficiaries.

/s/ Jessica L. Lomm, as Attorney-in-Fact


The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.20 to $10.21, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.

The Reporting Person disclaims beneficial ownership of these securities and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of these securities for purposes of Section 16 or for any other purpose.

These shares are held by The Daniel H. Meyer Investment Trust d/t/d 5/15/92 (the "Investment Trust"). The Reporting Person is the grantor, trustee and beneficiary of the Investment Trust. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

These shares are held by the DHM 2012 Gift Trust (the "Gift Trust"). The Reporting Person's spouse is a co-trustee and beneficiary of the Gift Trust. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.


Class A Common Stock

The option will vest and become exercisable immediately prior to the 2026 annual meeting of stockholders of the issuer, subject to continued service through the vesting date.

/s/ Mark McKechnie, Attorney-in-Fact for Charles Pappis


Class A Common Stock

/s/ Mark McKechnie, Attorney-in-Fact for Haiping Dun


Class A Common Stock

/s/ Mark McKechnie, Attorney-in-Fact for Tracy Liu


Employee Stock Option (right to buy) Holding

Common Stock

This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of June 7, 2024.

Amount of securities beneficially owned includes 83 shares acquired under the Intercontinental Exchange, Inc. Employee Stock Purchase Plan on June 30, 2025.

The price range for the aggregate amount sold by the direct holder is $181.54 - $182.53. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $182.54 - $183.53. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $183.55 - $184.54. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $184.55 - $185.54. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $185.59 - $185.85. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The common stock number referred in Table I is an aggregate number and represents 1,079,262 shares of common stock, 26,702 unvested restricted stock units ("RSUs"), and 57,027 unvested performance based restricted stock units ("PSUs"), for which the performance period has been satisfied. The RSUs and PSUs vest over a three-year period, in which 33.33% of the units vest each year.

The satisfaction of the 2023, 2024 and 2025 three-year total shareholder return (TSR) PSUs and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2026, February 2027 and February 2028, respectively, and will be reported at the time of vesting. The satisfaction of the 2024 and 2025 three-year earnings before interest, taxes, depreciation, and amortization (EBITDA) PSUs and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2027 and February 2028, respectively, and will be reported at the time of vesting.

The satisfaction of the performance based restricted stock units granted as Deal Incentive Awards and the corresponding number of shares to be issued pursuant to these awards, will not be determined until December 2026, December 2027 and December 2028 and will be subject to additional time-based vesting conditions and, if applicable, a subsequent one-year holding period.

The price range for the aggregate amount sold by the direct holder is $181.47 - $182.46. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $182.49 - $183.48. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $183.49 - $184.48. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $184.49 - $185.48. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

The price range for the aggregate amount sold by the direct holder is $185.50 - $185.85. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.

As previously reported, the reporting person also indirectly owns 1,951,705 shares that are beneficially owned directly by CPEX. The reporting person beneficially owns 100% of the equity interest in CPEX. Additionally, as previously reported, the reporting person indirectly owns shares that are beneficially owned directly by the reporting person's spouse for which the reporting person disclaims beneficial ownership.

As previously reported, the reporting person also indirectly owns 81,570 shares that are beneficially owned directly by the reporting person's spouse for which the reporting person disclaims beneficial ownership.

These options are fully vested.

/s/ Octavia N. Spencer, Attorney-in-fact


Common Stock

Restricted stock units that vest three years from the date of grant and are settled in shares of Applied common stock.

Performance shares "banked" as a result of 2025 performance.  Performance shares vest at end of three-year program and are settled in shares of Applied common stock.

Shares withheld by Registrant to satisfy tax withholding obligations on vesting of performance shares.

Stock-only stock appreciation rights which become exercisable in annual increments of 25% commencing one year after the date of grant.

/s/ Patricia A. Comai POA for Warren E. Hoffner, III


The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2025.

/s/ James Edward Doyle by Mark Busch, attorney-in- fact


Common Stock

Common Stock

The exercise of the subject option was effected on a net cash settlement basis in a transaction directly with the issuer not involving the actual issuance of any shares of the underlying common stock.


Common Stock


The purchases reported herein were effected pursuant to a Rule 10b5-1 plan adopted by Hill City Holdings, LP ("Hill City") on June 5, 2025.

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $12.27 to $12.755.
The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request,
full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The securities are held of record by Hill City. ECP ControlCo, LLC is the managing member of Energy Capital Partners IV, LLC, which is the general partner
of Energy Capital Partners GP IV, LP, which is the general partner of each of (i) Energy Capital Partners IV-A, LP, (ii) Energy Capital Partners IV-B, LP, (iii)
Energy Capital Partners IV-C, LP, and (iv) Energy Capital Partners IV-D, LP (the "Funds"). Energy Capital Partners GP IV, LP is also the general partner of
Energy Capital Partners IV-B (Hill City IP), LP ("Hill City IP"). Each of (i) Energy Capital Partners IV-A, LP, (ii) Hill City IP, (iii) Energy Capital Partners IVC,
LP, and (iv) Energy Capital Partners IV-D, LP are the members of Hill City Holdings GP, LLC, which is the general partner of Hill City.

ECP ControlCo, LLC is controlled by its board of managers, which consists of Douglas Kimmelman, Peter Labbat, Tyler Reeder, Rahman D'Argenio, Raoul
Hughes and Xavier Robert, all of whom collectively share the power to vote and dispose of the securities beneficially owned by ECP ControlCo, LLC. As a
result of these relationships, each of the foregoing entities and individuals may be deemed to share beneficial ownership of the securities held of record by Hill
City. Each such entity and individual disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein.

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $12.8041 to $13.12.
The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request,
full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Due to filing limitations of the electronic filing system, each of ECP Fiber Holdings GP, LLC, ECP Fiber Holdings, LP, Hill City Holdings GP, LLC and Hill City Holdings, LP are filing a separate Form 4.


Common stock, par value $0.00001 per share

Non-Qualified Stock Option (right to buy) with limited SAR

Common stock; par value $0.00001 per share

This transaction was executed in multiple trades at prices ranging from $108.30 to $109.285. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer full information regarding the number of shares and the prices at which the transaction was effected.

The limited stock appreciation right ("SAR") and employee stock option were granted in tandem. Accordingly, the exercise of one results in the expiration of the other. The SAR may be exercised only during the period beginning on the first day following the date that a "Change in Control" of Issuer occurs (as defined in the related grant agreement) and ending on the thirtieth day following such date. Upon exercise, the grantee shall be able to receive an amount equal to the product computed by multiplying (i) the excess of the "Offer Value Per Share" over the exercise price of the underlying option by (ii) the number of shares with respect to which the SAR is being exercised; provided, that such amount shall only be payable in the event an "Offer" is made.

The "Offer Value Per Share" means the average selling price of Issuer's common stock during the period of 30 days ending on the date on which the SAR is exercised. "Offer" means any tender offer or exchange offer for outstanding shares of Issuer representing at least 30% of the total voting power of the stock of Issuer, or an offer to purchase assets from Issuer that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of Issuer, other than an offer made by Issuer.

The options vested in substantially equal one-third increments on each of the following dates: February 11, 2021, February 11, 2022 and February 11, 2023.

Reflects the number of shares underlying unexercised options solely with respect to the Reporting Person's February 11, 2020 stock option award.


This transaction was executed in multiple trades at prices ranging from $242.0299 to $242.34. The price reported reflects the weighted average
sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full
information regarding the number of shares and prices at which the transaction was effected.

Total includes 20 shares held as Joint Tenants with Reporting Person's spouse.


Shares beneficially owned directly by Braeside Capital, L.P. ("Braeside Capital").   Braeside Investments, LLC ("Braeside Investments") serves as the investment manager of Braeside Capital. As a co-manager of Braeside Investments, Mr. Stein may be deemed to beneficially own the shares beneficially owned directly by Braeside Capital. Mr. Stein disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Shares beneficially owned directly by a proprietary account under Braeside Investments, LLC.  Braeside Investments, LLC ("Braeside Investments") serves as the investment manager of Braeside Capital, L.P. and Braeside Capital II, L.P.  As a co-manager of Braeside Investments, Mr. Stein may be deemed to beneficially own the shares beneficially owned directly by Braeside Investments.   Mr. Stein disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Shares beneficially owned directly by Braeside Capital II, L.P. ("Braeside Capital II").  Braeside Investments serves as the investment manager of Braeside Capital II. As a co-manager of Braeside Investments, Mr. Stein may be deemed to beneficially own the shares beneficially owned directly by Braeside Capital II. Mr. Stein disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.


These shares were acquired under the Corporation's 2017 Plan for Non-Employee Directors in lieu of quarterly board retainer fees of $12,981.51.

/s/ Steven M. Bradford;                      by Power of Attorney


Common Stock

Shares surrendered to pay tax liability due on vesting of Restricted Stock Units

Each restricted stock unit represents a contingent right to receive one share of PHLT's common stock. The units were awarded at no cost to Reporting Person.

Restricted Stock Unit Award was granted on August 5, 2024 (the "Grant Date"). These Restricted Stock Units shall be allocated into the following three tranches: (i) Tranche 1, consisting of 21,469 Restricted Stock Units, (ii) Tranche 2, consisting of 21,469 Restricted Stock Units and (iii) Tranche 3, consisting of 22,120 Restricted Stock Units. Each Tranche shall vest upon the achievement of the applicable Target Revenue Amount during a Performance Period, and subject to Reporting Person's continuous service through each vesting date. "Target Revenue Amount" shall mean the Company's trailing twelve month Healthcare revenue for a Performance Period as reported in the Company's financial statements filed with the Securities and Exchange Committee on Form 10-K or Form 10-Q, as applicable. Each Target Revenue Amount is measured on the trailing twelve month Healthcare revenue of the Company for the preceding twelve months, measured on a quarterly basis (each, a "Performance Period").

For Tranche 1, Reporting Person shall have up to three years from the Grant Date for the Company to achieve the Tranche 1 Target Revenue Amount of $135M. If the Tranche 1 Target Revenue Amount is achieved before 12 months, Reporting Person vests in the Tranche 1 RSUs at 12 months. If the Tranche 1 Target Revenue Amount is achieved in month 13 - 36, Reporting Person vests in the Tranche 1 RSUs whenever the Tranche 1 Target Revenue Amount is achieved. If the Tranche 1 Target Revenue Amount is not achieved by 36 months, the RSUs tied to Tranche 1 are forfeited.

For Tranche 2, Reporting Person shall have up to three years to achieve the Tranche 2 Target Revenue Amount of $155M. If the Tranche 2 Target Revenue Amount is achieved before 24 months, Reporting Person vests in the Tranche 2 RSUS at 24 months. If the Tranche 2 Target Revenue Amount is achieved in month 25 - 36, Reporting Person vests in the Tranche 2 RSUs whenever the Tranche 2 Target Revenue Amount is achieved. If the Tranche 2 Target Revenue Amount is not achieved by 36 months, the RSUs tied to Tranche 2 are forfeited.

For Tranche 3, Reporting Person shall have up to four years to achieve the Tranche 3 Target Revenue Amount of $175M. If the Tranche 3 Target Revenue Amount is achieved before 36 months, Reporting Person vests in the Tranche 3 RSUs at 36 months. If the Tranche 3 Target Revenue Amount is achieved in month 37 - 48, Reporting Person vests in the Tranche 3 RSUs whenever the Tranche 3 Target Revenue Amount is achieved. If the Tranche 3 Target Revenue Amount is not achieved by 48 months, the RSUs tied to Tranche 3 are forfeited.


Common Stock

The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.13. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

The stock options are fully vested.


Common Stock

Represents shares relinquished by the Reporting Person in exchange for the Issuer's payment of federal and state tax withholding obligations of the Reporting Person resulting from the vesting of RSUs, in accordance with Rule 16b-3.

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2024.

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

The restricted stock units vest as to 1/16th of the total shares quarterly, with the first vesting having occurred on May 12, 2022, and subject to the continued service of the Reporting Person  on each vesting date.

/s/ Gina Mastantuono by Russell S. Elmer, Attorney-in-Fact


These shares were issued to the reporting person as part of her compensation for service as a director of the registrant.

/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: VIVIAN CHOW


Common Stock

This option became vested as to all the underlying shares of Common Stock on April 20, 2025.


The price in Column 4 is a weighted average sale price. The prices actually received ranged from $205.56 to $205.87. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.


Common Stock

The transaction(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

/s/ Jacqueline P. Canney by Russell S. Elmer, Attorney-in-Fact


Class A Common Stock

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A common stock.

Held by a trust, of which the reporting person is co-trustee, for the benefit of his immediate family members. The reporting person is the beneficial owner of the securities held by the trust.

One-third of the RSUs vested on May 12, 2025. The remainder of the RSUs vest in equal quarterly installments such that they will be fully vested on May 12, 2027. The RSUs do not have an expiration date.

The numbers of shares (including shares underlying RSUs) reported on this Form 4 have been adjusted to give effect to a 1-for-20 reverse stock split of the Issuer's Class A and Class B common stock that was effected on August 5, 2025.


Class A Common Stock

On January 27, 2025, the issuer effected a 25 to 1 reverse stock split of its Class A Common Stock. The number of shares of Class A Common Stock reported on this Form 4 has been adjusted to reflect the reverse stock split.

This Form 4 is being filed late due to inadvertent administrative error.


Common Stock

/s/ Nicholas Tzitzon by Russell S. Elmer, Attorney-in-Fact


Ordinary Shares

Represents a restricted share unit ("RSU") award. The RSUs will vest in three equal installments on each of August 12, 2026, August 12, 2027 and August 12, 2028.

Each RSU represents a contingent right to receive one ordinary share.

This option will vest in three equal installments on each of August 12, 2026, August 12, 2027 and August 12, 2028.


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.24 to $22.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Represents a grant of restricted stock units pursuant to the Issuer's 2021 Omnibus Incentive Plan. Each restricted stock unit represents the right to receive, upon vesting, one share of Common Stock. These restricted stock units will vest in equal, or nearly equal, installments on August 12, 2026, 2027, and 2028, subject to the reporting person's continuous employment through such date.


These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.39 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes 277 shares that were acquired on May 15, 2025 under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.10 to $46.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes 359 shares that were acquired on May 15, 2025 under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).